Top

Published in:

01-04-2011 | Preclinical study

RACK1 promotes breast carcinoma migration/metastasis via activation of the RhoA/Rho kinase pathway

Authors: Xi-Xi Cao, Jing-Da Xu, Jia-Wen Xu, Xiao-Li Liu, Yuan-Yuan Cheng, Qing-Quan Li, Zu-De Xu, Xiu-Ping Liu

Published in: Breast Cancer Research and Treatment | Issue 3/2011

Abstract

We aimed to gain a mechanistic understanding of the role of RACK1 in breast carcinoma migration/metastasis. Migration assays were conducted in breast carcinoma cell lines. siRNA targeting RACK1 as well as the Rho kinase inhibitor were also applied. Immunoprecipitation and immunofluorescence were used to study the RACK1/RhoA interaction. GTP-Rho pull-down assays were performed to assess the activation of RhoA. We also conducted immunohistochemistry in 160 breast carcinoma samples. Experiments in vitro showed that RACK1 promotes migration via interaction with RhoA and activation of the RhoA/Rho kinase pathway. Immunohistochemistry in 160 samples revealed that RACK1 is strongly correlated with accepted tumor spread indicators and RhoA (all P < 0.05). Kaplan–Meier survival analysis indicated a correlation between higher RACK1 expression and shorter survival times (P < 0.001). RACK1 is a prognostic factor that promotes breast carcinoma migration/metastasis by interacting with RhoA and activating the RhoA/Rho kinase pathway.

Available only for authorised users

McPherson K, Steel CM, Dixon JM (1994) ABC of breast diseases. Breast cancer epidemiology, risk factors and genetics. BMJ 309:1003–1006PubMed

Tjan-Heijnen VCG, Bult P, de Widt-Levert LM, Ruers TJ, Beex LVAM (2001) Micro-metastases in axillary lymph nodes: an increasing classification and treatment dilemma in breast cancer due to the introduction of the sentinel lymph node procedure. Breast Cancer Res Treat 70:81–88PubMedCrossRef

Cao XX, Xu JD, Xu JW, Liu XL, Cheng YY, Wang WJ, Li QQ, Chen Q, Xu ZD, Liu XP (2009) RACK1 promotes breast carcinoma proliferation and invasion/metastasis in vitro and in vivo. Breast Cancer Res Treat. doi:10.1007/s10549-009-0657-x (Epub ahead of print)

Cao XX, Xu JD, Liu XL, Xu JW, Wang WJ, Li QQ, Chen Q, Xu ZD, Liu XP (2009) RACK1: a superior independent predictor for poor clinical outcome in breast cancer. Int J Cancer. doi:10.1002/ijc.25120 (Epub ahead of print)

Ron D, Chen CH, Caldwell J, Jamieson L, Orr E, Mochly-Rosen D (1994) Cloning of an intracellular receptor for protein kinase C: a homolog of the beta subunit of G proteins. Proc Natl Acad Sci USA 91:839–843PubMedCrossRef

McCahill A, Warwicker J, Bolger GB, Houslay MD, Yarwood SJ (2002) The RACK1 scaffold protein: a dynamic cog in cell response mechanisms. Mol Pharmacol 62:1261–1273PubMedCrossRef

Kubota T, Yokosawa N, Yokota S, Fujii N (2002) Association of mumps virus V protein with RACK1 results in dissociation of STAT-1 from the alpha interferon receptor complex. J Virol 76:12676–12682PubMedCrossRef

Hermanto U, Zong CS, Li W, Wang LH (2002) RACK1, an insulin-like growth factor I (IGF-I) receptor-interacting protein, modulates IGF-I-dependent integrin signaling and promotes cell spreading and contact with extracellular matrix. Mol Cell Biol 22:2345–2365PubMedCrossRef

Wu Di, Asiedu Michael, Wei Qize (2009) MyoGEF regulates the invasion activity of MDA-MB-231 breast cancer cells through activation of RhoA and RhoC. Oncogene 28:2219–2230PubMedCrossRef

10.

Pillé JY, Denoyelle C, Varet J, Bertrand JR, Soria J, Opolon P, Lu H, Pritchard LL, Vannier JP, Malvy C, Soria C, Li H (2005) Anti-RhoA and anti-RhoC siRNAs inhibit the proliferation and invasiveness of MDA-MB-231 breast cancer cells in vitro and in vivo. Mol Ther 11:267–274PubMedCrossRef

11.

Simpson KJ, Dugan AS, Mercurio AM (2004) Functional analysis of the contribution of RhoA and RhoC GTPases to invasive breast carcinoma. Cancer Res 64:8694–8701PubMedCrossRef

12.

van Golen KL, Wu ZF, Qiao XT, Bao LW, Merajver SD (2000) RhoC GTPase, a novel transforming oncogene for human mammary epithelial cells that partially recapitulates the inflammatory breast cancer phenotype. Cancer Res 60:5832–5838PubMed

13.

Davies R, Budworth J, Riley J, Snowden R, Gescher A, Gant TW (1996) Regulation of P-glycoprotein 1 and 2 gene expression and protein activity in two MCF7/ADR cell line subclones. Br J Cancer 73:307–315PubMedCrossRef

14.

McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM (2006) Reporting recommendations for tumor marker prognostic studies (REMARK). Breast Cancer Res Treat 100:229–235PubMedCrossRef

15.

Boettner B, Van Aelst L (2002) The role of Rho GTPases in disease development. Gene 286:155–174PubMedCrossRef

16.

Buensuceso CS, Woodside D, Huff JL, Plopper GE, O’Toole TE (2001) The WD protein Rack1 mediates protein kinase C and integrin-dependent cell migration. J Cell Sci 114:1691–1698PubMed

17.

Schechtman D, Mochly-Rosen D (2001) Adaptor proteins in protein kinase C-mediated signal transduction. Oncogene 20:6339–6347PubMedCrossRef

18.

Sklan EH, Podoly E, Soreq H (2006) RACK1 has the nerve to act: structure meets function in the nervous system. Prog Neurobiol 78:117–134PubMedCrossRef

19.

Imai Y, Suzuki Y, Tohyama M, Wanaka A, Takagi T (1994) Cloning and expression of a neural differentiation-associated gene, p205, in the embryonal carcinoma cell line P19 and in the developing mouse. Brain Res Mol Brain Res 24:313–319PubMedCrossRef

20.

Berns H, Humar R, Hengerer B, Kiefer FN, Battegay EJ (2000) RACK1 is up-regulated in angiogenesis and human carcinomas. FASEB J 14:2549–2558PubMedCrossRef

21.

Yoshiji H, Kuriyama S, Ways DK, Yoshii J, Miyamoto Y, Kawata M, Ikenaka Y, Tsujinoue H, Nakatani T, Shibuya M, Fukui H (1999) Protein kinase C lies on the signaling pathway for vascular endothelial growth factor-mediated tumor development and angiogenesis. Cancer Res 59:4413–4418PubMed

22.

Bouzahzah B, Albanese C, Ahmed F, Pixley F, Lisanti MP, Segall JD, Condeelis J, Joyce D, Minden A, Der CJ, Chan A, Symons M, Pestell RG (2001) Rho family GTPases regulate mammary epithelium cell growth and metastasis through distinguishable pathways. Mol Med 7:816–830PubMed

23.

Denoyelle C, Vasse M, Körner M, Mishal Z, Ganné F, Vannier JP, Soria J, Soria C (2001) Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits the signaling pathways involved in the invasiveness and metastatic properties of highly invasive breast cancer celllines: an in vitro study. Carcinogenesis 22:1139–1148PubMedCrossRef

24.

Bourguignon LY (2001) CD44-mediated oncogenic signaling and cytoskeleton activation during mammary tumor progression. J Mammary Gland Biol Neoplasia 6:287–297PubMedCrossRef

25.

Burridge K, Wennerberg K (2004) Rho and Rac take center stage. Cell 116:167–179PubMedCrossRef

26.

Nobes CD, Hall A (1995) Rho, rac, and cdc42 GTPases regulate the assembly of multimolecular focal complexes associated with actin stress fibers, lamellipodia, and filopodia. Cell 81:53–62PubMedCrossRef

27.

Caron E, Hall A (1998) Identification of two distinct mechanisms of phagocytosis controlled by different Rho GTPases. Science 282:1717–1721PubMedCrossRef

28.

Pertz O, Hodgson L, Klemke RL, Hahn KM (2006) Spatiotemporal dynamics of RhoA activity in migrating cells. Nature 440:1069–1072PubMedCrossRef

29.

Narumiya S, Tanji M, Ishizaki T (2009) Rho signaling, ROCK and mDia1, in transformation, metastasis and invasion. Cancer Metastasis Rev 28:65–76PubMedCrossRef

30.

Amano M, Chihara K, Kimura K, Fukata Y, Nakamura N, Mastuura Y, Kaibuchi K (1997) Formation of actin stress fibers and focal adhesion enhanced by Rho-kinase. Science 275:1308–1311PubMedCrossRef

31.

Ishizaki T, Uehata M, Tamechika I, Keel J, Nonomura K, Maekawa M, Narumiya S (2000) Pharmacological properties of Y-27632, a specific inhibitor of Rho-associated kinase. Mol Pharmacol 57:976–983PubMed

32.

Sahai E, Ishizaki T, Narumiya S, Treisman R (1999) Transformation mediated by Rho requires activity of ROCK kinases. Curr Biol 9:136–145PubMedCrossRef

33.

Itoh K, Yoshioka K, Akedo H, Uehata M, Ishizaki T, Narumiya S (1999) An essential part for Rho-associated kinase in the transcellular invasion of tumor cells. Nat Med 5:221–225PubMedCrossRef

34.

Del Re DP, Miyamoto S, Brown JH (2008) Focal adhesion kinase as a RhoA-activable signaling scaffold mediating Akt activation and cardiomyocyte protection. J Biol Chem 283:35622–35629PubMedCrossRef

35.

Nakaya Y, Sukowati EW, Wu Y, Sheng G (2008) RhoA and microtubule dynamics control cell-basement membrane interaction in EMT during gastrulation. Nat Cell Biol 10:765–775PubMedCrossRef

Title: RACK1 promotes breast carcinoma migration/metastasis via activation of the RhoA/Rho kinase pathway
Authors: Xi-Xi Cao
Jing-Da Xu
Jia-Wen Xu
Xiao-Li Liu
Yuan-Yuan Cheng
Qing-Quan Li
Zu-De Xu
Xiu-Ping Liu
Publication date: 01-04-2011
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 3/2011
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-010-0955-3

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2011

Bone mineral density and risk of postmenopausal breast cancer

Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, oestrogen receptor-positive breast cancer patients. Very late results of the ‘gruppo di ricerca per la chemio-ormonoterapia adiuvante (GROCTA)’ 01-Trial in early breast cancer

Validating the meta-analytical results on MDM2, CASP8, XRCC3 polymorphisms and breast cancer risk: examination of Hardy–Weinberg Equilibrium

Age-related variation in the relationship between menopausal hormone therapy and the risk of dying from breast cancer

Let-7a regulation of insulin-like growth factors in breast cancer

PALB2 germline mutations in familial breast cancer cases with personal and family history of pancreatic cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer